Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy

Weon Sup Shin, Jiyou Han, Peter Verwilst, Rajesh Kumar, Jong-Hoon Kim, Jong Seung Kim

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The development of targeted and effective theranostic (therapeutic and diagnostic) chemotherapeutic agents is highly desirable for precise diagnosis and treatment of cancer. To realize this goal, we developed a cancer-targeting and enzyme-triggered theranostic prodrug 1, containing 7-ethyl-10-hydroxycamptothecin (SN-38), a well-known anticancer drug, which inhibits topoisomerase I in the cell nucleus; hydroquinone as an enzyme-triggered moiety; and biotin as a cancer targeting unit. Enzyme-triggered theranostic prodrug 1 selectively targets cancer cells and is subsequently activated in the presence of NAD(P)H: quinone oxidoreductase-1 (NQO1), a cytosolic flavoprotein that catalyzes the two-electron reduction of quinone moieties with the concomitant consumption of NADH or NADPH as electron donors. High levels of NQO1 were found in a variety of cancer cell lines compared to healthy cells, and therefore, it is an excellent target for the development of cancer targeted drug delivery systems. Upon preferential cancer cell delivery and uptake, aided by biotin, the enzyme-triggered theranostic prodrug 1 is cleaved by NQO1, with the subsequent release of SN-38, inhibiting topoisomerase I, leading to apoptosis. The drug release and induced apoptosis of cancer cells expressing both biotin receptors and high levels of NQO1 was simultaneously monitored via the innate fluorescence of the released SN-38 by confocal microscopy. In vitro and in vivo studies showed an effective inhibition of cancer growth by the enzyme-triggered theranostic prodrug 1. Thus, this type of enzyme-triggered targeted prodrug therapy is an interesting and promising approach for future cancer treatment.

Original languageEnglish
Pages (from-to)1419-1426
Number of pages8
JournalBioconjugate Chemistry
Volume27
Issue number5
DOIs
Publication statusPublished - 2016 May 18

Fingerprint

irinotecan
Chemotherapy
Prodrugs
Enzymes
Cells
Drug Therapy
Neoplasms
Type I DNA Topoisomerase
Cell death
Biotin
NAD
Apoptosis
Enzyme inhibition
Flavoproteins
Therapeutics
Oncology
Electrons
Confocal microscopy
NADP
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Cancer Targeted Enzymatic Theranostic Prodrug : Precise Diagnosis and Chemotherapy. / Shin, Weon Sup; Han, Jiyou; Verwilst, Peter; Kumar, Rajesh; Kim, Jong-Hoon; Kim, Jong Seung.

In: Bioconjugate Chemistry, Vol. 27, No. 5, 18.05.2016, p. 1419-1426.

Research output: Contribution to journalArticle

Shin, Weon Sup ; Han, Jiyou ; Verwilst, Peter ; Kumar, Rajesh ; Kim, Jong-Hoon ; Kim, Jong Seung. / Cancer Targeted Enzymatic Theranostic Prodrug : Precise Diagnosis and Chemotherapy. In: Bioconjugate Chemistry. 2016 ; Vol. 27, No. 5. pp. 1419-1426.
@article{7c2d4ef8dae347dbbd3059a05fc157a4,
title = "Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy",
abstract = "The development of targeted and effective theranostic (therapeutic and diagnostic) chemotherapeutic agents is highly desirable for precise diagnosis and treatment of cancer. To realize this goal, we developed a cancer-targeting and enzyme-triggered theranostic prodrug 1, containing 7-ethyl-10-hydroxycamptothecin (SN-38), a well-known anticancer drug, which inhibits topoisomerase I in the cell nucleus; hydroquinone as an enzyme-triggered moiety; and biotin as a cancer targeting unit. Enzyme-triggered theranostic prodrug 1 selectively targets cancer cells and is subsequently activated in the presence of NAD(P)H: quinone oxidoreductase-1 (NQO1), a cytosolic flavoprotein that catalyzes the two-electron reduction of quinone moieties with the concomitant consumption of NADH or NADPH as electron donors. High levels of NQO1 were found in a variety of cancer cell lines compared to healthy cells, and therefore, it is an excellent target for the development of cancer targeted drug delivery systems. Upon preferential cancer cell delivery and uptake, aided by biotin, the enzyme-triggered theranostic prodrug 1 is cleaved by NQO1, with the subsequent release of SN-38, inhibiting topoisomerase I, leading to apoptosis. The drug release and induced apoptosis of cancer cells expressing both biotin receptors and high levels of NQO1 was simultaneously monitored via the innate fluorescence of the released SN-38 by confocal microscopy. In vitro and in vivo studies showed an effective inhibition of cancer growth by the enzyme-triggered theranostic prodrug 1. Thus, this type of enzyme-triggered targeted prodrug therapy is an interesting and promising approach for future cancer treatment.",
author = "Shin, {Weon Sup} and Jiyou Han and Peter Verwilst and Rajesh Kumar and Jong-Hoon Kim and Kim, {Jong Seung}",
year = "2016",
month = "5",
day = "18",
doi = "10.1021/acs.bioconjchem.6b00184",
language = "English",
volume = "27",
pages = "1419--1426",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Cancer Targeted Enzymatic Theranostic Prodrug

T2 - Precise Diagnosis and Chemotherapy

AU - Shin, Weon Sup

AU - Han, Jiyou

AU - Verwilst, Peter

AU - Kumar, Rajesh

AU - Kim, Jong-Hoon

AU - Kim, Jong Seung

PY - 2016/5/18

Y1 - 2016/5/18

N2 - The development of targeted and effective theranostic (therapeutic and diagnostic) chemotherapeutic agents is highly desirable for precise diagnosis and treatment of cancer. To realize this goal, we developed a cancer-targeting and enzyme-triggered theranostic prodrug 1, containing 7-ethyl-10-hydroxycamptothecin (SN-38), a well-known anticancer drug, which inhibits topoisomerase I in the cell nucleus; hydroquinone as an enzyme-triggered moiety; and biotin as a cancer targeting unit. Enzyme-triggered theranostic prodrug 1 selectively targets cancer cells and is subsequently activated in the presence of NAD(P)H: quinone oxidoreductase-1 (NQO1), a cytosolic flavoprotein that catalyzes the two-electron reduction of quinone moieties with the concomitant consumption of NADH or NADPH as electron donors. High levels of NQO1 were found in a variety of cancer cell lines compared to healthy cells, and therefore, it is an excellent target for the development of cancer targeted drug delivery systems. Upon preferential cancer cell delivery and uptake, aided by biotin, the enzyme-triggered theranostic prodrug 1 is cleaved by NQO1, with the subsequent release of SN-38, inhibiting topoisomerase I, leading to apoptosis. The drug release and induced apoptosis of cancer cells expressing both biotin receptors and high levels of NQO1 was simultaneously monitored via the innate fluorescence of the released SN-38 by confocal microscopy. In vitro and in vivo studies showed an effective inhibition of cancer growth by the enzyme-triggered theranostic prodrug 1. Thus, this type of enzyme-triggered targeted prodrug therapy is an interesting and promising approach for future cancer treatment.

AB - The development of targeted and effective theranostic (therapeutic and diagnostic) chemotherapeutic agents is highly desirable for precise diagnosis and treatment of cancer. To realize this goal, we developed a cancer-targeting and enzyme-triggered theranostic prodrug 1, containing 7-ethyl-10-hydroxycamptothecin (SN-38), a well-known anticancer drug, which inhibits topoisomerase I in the cell nucleus; hydroquinone as an enzyme-triggered moiety; and biotin as a cancer targeting unit. Enzyme-triggered theranostic prodrug 1 selectively targets cancer cells and is subsequently activated in the presence of NAD(P)H: quinone oxidoreductase-1 (NQO1), a cytosolic flavoprotein that catalyzes the two-electron reduction of quinone moieties with the concomitant consumption of NADH or NADPH as electron donors. High levels of NQO1 were found in a variety of cancer cell lines compared to healthy cells, and therefore, it is an excellent target for the development of cancer targeted drug delivery systems. Upon preferential cancer cell delivery and uptake, aided by biotin, the enzyme-triggered theranostic prodrug 1 is cleaved by NQO1, with the subsequent release of SN-38, inhibiting topoisomerase I, leading to apoptosis. The drug release and induced apoptosis of cancer cells expressing both biotin receptors and high levels of NQO1 was simultaneously monitored via the innate fluorescence of the released SN-38 by confocal microscopy. In vitro and in vivo studies showed an effective inhibition of cancer growth by the enzyme-triggered theranostic prodrug 1. Thus, this type of enzyme-triggered targeted prodrug therapy is an interesting and promising approach for future cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84971265317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971265317&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.6b00184

DO - 10.1021/acs.bioconjchem.6b00184

M3 - Article

C2 - 27135737

AN - SCOPUS:84971265317

VL - 27

SP - 1419

EP - 1426

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 5

ER -